<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820270</url>
  </required_header>
  <id_info>
    <org_study_id>AutoTregIsl</org_study_id>
    <nct_id>NCT04820270</nct_id>
  </id_info>
  <brief_title>Infusion of Autologous T Regulatory Cells (T Reg) at the Time of Transplantation of Allogenic Islets of Langerhans</brief_title>
  <official_title>Infusion of Autologous T Regulatory Cells (T Reg) at the Time of Transplantation of Allogenic Islets of Langerhans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Nordic Network For Clinical Islet Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Nordic Network For Clinical Islet Transplantation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open single armed study to investigate safety and feasibility of administrating autologous T&#xD;
      regulatory cells at the time of allogenic islet transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open single armed study to investigate safety and feasibility of administrating autologous T&#xD;
      regulatory cells at the time of allogenic islet transplantation. Patients are recruited from&#xD;
      the waiting list for islet transplantation within The Nordic Network for Clinical Islet&#xD;
      Transplantation. Patients included in the study will undergo apheresis while on the waiting&#xD;
      list. T regulatory cells will be sorted out and frozen. Autologous, non modified T regs will&#xD;
      then be infused simultaneously intraportally with the islet graft at transplantation.&#xD;
      Patients will be followed for safety and efficacy regarding the islet transplantation over&#xD;
      three months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm feasibility and safety study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding</measure>
    <time_frame>0-1 days post transplant</time_frame>
    <description>Number of patients with &gt;20g/L reduction of haemoglobine and signs of bleeding shown by ultrasound post operative day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombosis</measure>
    <time_frame>0-75 days post transplant</time_frame>
    <description>Number of patients with thrombosis in portal veins shown by ultrasound post operative day 1 or later</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver function</measure>
    <time_frame>0-75days</time_frame>
    <description>Number of patients with an elevation of transaminases &gt; 5 times upper normal level during follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infections</measure>
    <time_frame>0-90 days post transplantation</time_frame>
    <description>Number of treatment requiering infections in each patient during follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Islet graft failure</measure>
    <time_frame>day 75</time_frame>
    <description>Number of patients with islet graft failure shown as C peptide &lt;0.1 nmol/L fasting or &lt;0.3 nmol/L (90min) at a MMTT day 75 or lack of improvement compared to baseline if transplanted before.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunization</measure>
    <time_frame>90 days post transplantation</time_frame>
    <description>Number of patients with new anti HLA antibodies found at 90 days post transplantation compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Islet function</measure>
    <time_frame>day 75</time_frame>
    <description>Fraction of patients with a C-peptide level above 0.1 nmol/L fasting or 0.3 nmol/L (90min) at a MMTT day 75</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin independence</measure>
    <time_frame>day 75</time_frame>
    <description>Fraction of patients without need of exogeous insulin (ADA criteria) at day 75 post transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>day 75</time_frame>
    <description>Mean reduction of HbA1c at day 75 compared to baseline(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic unawareness</measure>
    <time_frame>day 75</time_frame>
    <description>Number of patients with a reduced Clarke hypoglycemia awareness score day 75 (+/-5) post transplantation compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c and hypoglycemic unawareness combined</measure>
    <time_frame>day 75</time_frame>
    <description>Number of patients with both a HbA1c ≤ 6.5% (DCCT) and lack of severe hypoglycemia at day 75 post transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRA level</measure>
    <time_frame>day 90</time_frame>
    <description>Number of patients with a rise in PRA (panel reactive antibodies) with more than 10% at 90 days post transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>Autologous Tregs in allogenic islet transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Tregs are given simultaneously to the patient with the islets</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous T regulatory cells</intervention_name>
    <description>Enriched autologous T regulatory cells are given back to the patient at the time of islet transplantation</description>
    <arm_group_label>Autologous Tregs in allogenic islet transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be registered on the waiting list within The Nordic Network for Clinical&#xD;
             Islet Transplantation&#xD;
&#xD;
          -  Type 1 diabetes with diagnosed &lt;40years of age and with&gt;5 years of exogenous insulin&#xD;
             use&#xD;
&#xD;
          -  C peptide &lt; 0.1 nmol/L at MMTT if no previous islet transplant&#xD;
&#xD;
          -  Adequate previous treatment by an experienced diabetologist&#xD;
&#xD;
          -  Patient must understand and be able to sign an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a previous transplant other than islets&#xD;
&#xD;
          -  Patient with an BMI&gt;30&#xD;
&#xD;
          -  Patient with an need of more than 1U/kg of insulin per 24h&#xD;
&#xD;
          -  Repeated abnormal liver function tests&#xD;
&#xD;
          -  non stable retinopathy&#xD;
&#xD;
          -  known abnormalities in coagulation&#xD;
&#xD;
          -  known malignancies&#xD;
&#xD;
          -  non stable heart conditions&#xD;
&#xD;
          -  active infections&#xD;
&#xD;
          -  serological proof of hepatitis B or C or HIV&#xD;
&#xD;
          -  signs of portal hypertension&#xD;
&#xD;
          -  patients that are pregnant, breast feeding or aim to become pregnant during the study&#xD;
             period&#xD;
&#xD;
          -  patients with a PRA &gt; 20%, positive cross match or known DSA&#xD;
&#xD;
          -  patients with conditions that the investigator would consider unsafe to combine with&#xD;
             islet transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torbjörn Lundgren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transplantation</keyword>
  <keyword>Islets of Langerhans</keyword>
  <keyword>T regulatory Cells (autologous)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

